InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,165.68
(
0.74%
)
US TECH 100
17,554.80
(
0.78%
)
Dow Jones
38,759.78
(
0.22%
)
Brent Oil
83.32
(
0.23%
)
Bitcoin
62,785.66
(
-1.90%
)
Post# of 251728
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119576
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 201481

Tuesday, 06/07/2016 10:08:40 AM

Tuesday, June 07, 2016 10:08:40 AM

Post# of 251728
CLCD completes enrollment in first phase-3 migraine study:

http://finance.yahoo.com/news/colucid-pharmaceuticals-announces-last-patient-120000366.html

SAMURAI top-line data are expected to be released when available in the third quarter of 2016, with more detailed results to be presented at a symposium during the 5th European Headache and Migraine Trust International Congress (EHMTIC 2016) taking place in Glasgow, Scotland on September 17th, 2016.

Please see #msg-122768874 for background.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up